Neoadjuvant therapy for pancreatic cancer: A current review
β Scribed by Daniel E. Abbott; Marshall S. Baker; Mark S. Talamonti
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 219 KB
- Volume
- 101
- Category
- Article
- ISSN
- 0022-4790
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract Pancreatic cancer is uniformly fatal unless it can be surgically resected. Survival rates for the 15% to 20% of patients who have resectable disease, however, are a disappointing 10% to 30%, depending on the status of margins and surrounding lymph nodes. In the midβ1980s, a landmark stu
It has been approximately 7 years since the introduction of gene therapy. Since conventional procedures such as surgery, chemotherapy, and radiotherapy have had limited therapeutic value for cancer patients, the evolution of gene therapy seems a promising alternative to many researchers and clinicia